The present invention concerns a method to modulate the level of or to modify a target molecule in a subject or an environment, said method comprising: administering in said subject or providing to said environment an engineered bacterial strain comprising (i) a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, wherein the expression of said molecule of interest modulates directly or indirectly the level of or modify the target molecule in said subject or environment and (ii) an autologous gene or gene set involved in the import and/or metabolism of a milk oligosaccharide; and further administering to said subject, or providing to said environment, said milk oligosaccharide; whereby the level of the target molecule in said subject or environment is modulated or the target molecule is modified in said subject or environment.

Described herein are pharmaceutical compositions for the oral administration of nicotinamide, or a combination of nicotinamide and mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of nicotinamide or a combination of nicotinamide and mesalazine.

Provided is a probiotic composition, comprising at least one genus of mixotrophic microorganism and a carrier and pharmaceutical preparations comprising such a composition for use in the treatment of bloating in an animal. Also provided are methods of use of such pharmaceutical preparations in the treatment of bloating in an animal.

Provided is a probiotic composition, comprising at least one genus of mixotrophic microorganism and a carrier and pharmaceutical preparations comprising such a composition for use in the treatment of bloating in an animal. Also provided are methods of use of such pharmaceutical preparations in the treatment of bloating in an animal.

Disclosed herein are compositions and methods for use in treating gastroparesis.

Disclosed herein are compositions and methods for use in treating gastroparesis.

Disclosed herein is an ingestible composition comprising a sphingan and its use as a prebiotic.

Disclosed herein is an ingestible composition comprising a sphingan and its use as a prebiotic.

Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.